Arecor and Medtronic say they partnered to create a new type of insulin that would allow for the use of new insulin pump designs.
These new insulin pumps in mind would sit under the skin, rather than on the surface of the skin. The research collaboration aims to develop a novel, high-concentration, thermostable insulin for use by Medtronic in a next-generation pump. A new insulin of this kind could minimize the need for pump maintenance interventions and expand utility for physicians while saving costs.
Arecor and Medtronic’s new insulin remains at an early stage in development and would still require clinical trials.
Gary Dulak, senior director of new venture programs at Medtronic Diabetes explained the potential difference made by the new type of insulin delivered by an implantable pump:
